120 related articles for article (PubMed ID: 16867695)
1. Pharmacokinetics of vinpocetine and its metabolite, apovincaminic acid, in plasma and cerebrospinal fluid after intravenous infusion.
Polgár M; Vereczkey L; Nyáry I
J Pharm Biomed Anal; 1985; 3(2):131-9. PubMed ID: 16867695
[TBL] [Abstract][Full Text] [Related]
2. Effect of age on the pharmacokinetics of vinpocetine (Cavinton) and apovincaminic acid.
Miskolczi P; Vereczkey L; Szalay L; Göndöc C
Eur J Clin Pharmacol; 1987; 33(2):185-9. PubMed ID: 3691609
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of vinpocetine and its main metabolite apovincaminic acid before and after the chronic oral administration of vinpocetine to humans.
Miskolczi P; Kozma K; Polgár M; Vereczkey L
Eur J Drug Metab Pharmacokinet; 1990; 15(1):1-5. PubMed ID: 2384112
[TBL] [Abstract][Full Text] [Related]
4. Cerebral circulatory and cardiac effects of vinpocetine and its metabolite, apovincaminic acid, in anesthetized dogs.
Imamoto T; Tanabe M; Shimamoto N; Kawazoe K; Hirata M
Arzneimittelforschung; 1984; 34(2):161-9. PubMed ID: 6539108
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of apovincaminic acid in dogs.
Vereczkey L; Pudleiner P
Pol J Pharmacol Pharm; 1987; 39(2):161-5. PubMed ID: 3432163
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective effects of vinpocetine and its major metabolite cis-apovincaminic acid on NMDA-induced neurotoxicity in a rat entorhinal cortex lesion model.
Nyakas C; Felszeghy K; Szabó R; Keijser JN; Luiten PG; Szombathelyi Z; Tihanyi K
CNS Neurosci Ther; 2009; 15(2):89-99. PubMed ID: 19492990
[TBL] [Abstract][Full Text] [Related]
7. Kinetic metabolism of vinpocetine in the rat.
Vereczkey L; Szentirmay Z; Szporny L
Arzneimittelforschung; 1979; 29(6):953-6. PubMed ID: 582790
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of vinpocetine in humans.
Vereczkey L; Czira G; Tamás J; Szentirmay Z; Botár Z; Szporny L
Arzneimittelforschung; 1979; 29(6):957-60. PubMed ID: 582791
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and comparative bioavailability of two vinpocetine tablet formulations in healthy volunteers by using the metabolite apovincaminic acid as pharmacokinetic parameter.
Vlase L; Bodiu B; Leucuta SE
Arzneimittelforschung; 2005; 55(11):664-8. PubMed ID: 16366040
[TBL] [Abstract][Full Text] [Related]
10. Vinpocetine pharmacokinetics in elderly subjects.
Grandt R; Beitinger H; Schaltenbrand R; Braun W
Arzneimittelforschung; 1989 Dec; 39(12):1599-602. PubMed ID: 2624613
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of vinpocetine and apovincaminic acid in patients with impaired renal function.
Miskolczi P; Vereczkey L; Szalay L; Göndöcs CS
Eur J Drug Metab Pharmacokinet; 1984; 9(2):169-75. PubMed ID: 6745306
[TBL] [Abstract][Full Text] [Related]
12. [Human positron emission tomography with oral 11C-vinpocetine].
Vas A; Christer H; Sóvágó J; Johan S; Cselényi Z; Kiss B; Kárpáti E; Lars F; Gulyás B
Orv Hetil; 2003 Nov; 144(46):2271-6. PubMed ID: 14702922
[TBL] [Abstract][Full Text] [Related]
13. Study on the absorption of vinpocetine and apovincaminic acid.
Pudleiner P; Vereczkey L
Eur J Drug Metab Pharmacokinet; 1993; 18(4):317-21. PubMed ID: 8020528
[TBL] [Abstract][Full Text] [Related]
14. Clinical Pharmacology of Vinpocetine: Properties Revisited and Introduction of a Population Pharmacokinetic Model for Its Metabolite, Apovincaminic Acid (AVA).
Petric Z; Paixão P; Filipe A; Guimarães Morais J
Pharmaceutics; 2023 Oct; 15(10):. PubMed ID: 37896263
[TBL] [Abstract][Full Text] [Related]
15. [Neuroprotective effects of vinpocetine in vivo and in vitro. Apovincaminic acid derivatives as potential therapeutic tools in ischemic stroke].
Dézsi L; Kis-Varga I; Nagy J; Komlódi Z; Kárpáti E
Acta Pharm Hung; 2002; 72(2):84-91. PubMed ID: 12498034
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of vinpocetine (Cavinton) in dog.
Polgár M; Vereczkey L
Pol J Pharmacol Pharm; 1984; 36(4):407-12. PubMed ID: 6527972
[TBL] [Abstract][Full Text] [Related]
17. Clinical and non-clinical investigations using positron emission tomography, near infrared spectroscopy and transcranial Doppler methods on the neuroprotective drug vinpocetine: a summary of evidences.
Vas A; Gulyás B; Szabó Z; Bönöczk P; Csiba L; Kiss B; Kárpáti E; Pánczél G; Nagy Z
J Neurol Sci; 2002 Nov; 203-204():259-62. PubMed ID: 12417394
[TBL] [Abstract][Full Text] [Related]
18. Metabolism of ethyl apovincaminate in the rat.
Vereczkey L; Szporny L
Arzneimittelforschung; 1976; 26(10a):1933-8. PubMed ID: 1037219
[TBL] [Abstract][Full Text] [Related]
19. Role of sodium channel inhibition in neuroprotection: effect of vinpocetine.
Bönöczk P; Gulyás B; Adam-Vizi V; Nemes A; Kárpáti E; Kiss B; Kapás M; Szántay C; Koncz I; Zelles T; Vas A
Brain Res Bull; 2000 Oct; 53(3):245-54. PubMed ID: 11113577
[TBL] [Abstract][Full Text] [Related]
20. PET studies on the brain uptake and regional distribution of [11C]vinpocetine in human subjects.
Gulyás B; Halldin C; Sandell J; Karlsson P; Sóvágó J; Kárpáti E; Kiss B; Vas A; Cselényi Z; Farde L
Acta Neurol Scand; 2002 Dec; 106(6):325-32. PubMed ID: 12460136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
